This database contains 60 studies, archived under the term: "events"
Click here to filter this large number of results.
Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
Emre, Murat,
Tsolaki, Magda,
Bonuccelli, Ubaldo,
Destée, Alain,
Tolosa, Eduardo,
Kutzelnigg, Alexandra,
Ceballos-Baumann, Andrés,
Zdravkovic, Slobodan,
Bladström, Anna,
Jones, Roy
Background: Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed. Therefore, the efficacy and safety of memantine were investigated in patients with mild to moderate Parkinson’s disease dementia (PDD) or dementia with Lewy bodies (DLB).; Methods: Patients (≥50 years […]
Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial
Culo, Sandi,
Mulsant, Benoit H.,
Rosen, Jules,
Mazumdar, Sati,
Blakesley, Richard E.,
Houck, Patricia R.,
Pollock, Bruce G.
Sensitivity to psychotropic medications presents a therapeutic challenge when treating neuropsychiatric symptoms in patients with dementia with Lewy bodies (DLB). We compared under randomized, double-blinded conditions the tolerability and efficacy of citalopram and risperidone in the treatment of behavioral and psychotic symptoms in patients with DLB and Alzheimer disease (AD). Thirty-one participants with DLB and […]
Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
Siemers, Eric R.,
Friedrich, Stuart,
Dean, Robert A.,
Gonzales, Celedon R.,
Farlow, Martin R.,
Paul, Steven M.,
Demattos, Ronald B.
Objectives: Active and passive immunization strategies have been suggested as possible options for the treatment of Alzheimer disease (AD). LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD.; Methods: Patients with mild to moderate AD were screened and selected for inclusion. Initial screening was performed for 54 subjects, […]
Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease
Blesa González, R.,
Boada Rovira, M.,
Martínez Parra, C.,
Gil-Saladié, D.,
Almagro, C. A.,
Gobartt Vázquez, A. L.
Introduction: Rivastigmine transdermal patches for the treatment of Alzheimer’s disease (AD) have potential benefits compared to capsules because of their sustained absorption through the skin, good local tolerability and reduction of gastrointestinal problems.; Purpose: To assess gastrointestinal and skin tolerability and the need for optimal dose titration of rivastigmine transdermal patches in Alzheimer’s disease patients […]
Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer’s disease: results of a 16-week open-label trial
Schulz, Jörg B.,
Rainer, Michael,
Klünemann, Hans-Hermann,
Kurz, Alexander,
Wolf, Stefanie,
Sternberg, Kati,
Tennigkeit, Frank
The present study evaluated the effects of once-daily memantine (20 mg) treatment on cognition and communication in patients with moderate to severe Alzheimer’s disease (AD). In a multicenter, single-arm open-label study, outpatients diagnosed with AD (MMSE < 20; n = 97) were titrated from 5 mg to 20 mg once-daily memantine over 4 weeks. Once-daily […]
Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation
Lott, Ira T.,
Doran, Eric,
Nguyen, Vinh Q.,
Tournay, Anne,
Head, Elizabeth,
Gillen, Daniel L.
Individuals with Down syndrome over age 40 years are at risk for developing dementia of the Alzheimer type and have evidence for chronic oxidative stress. There is a paucity of treatment trials for dementia in Down syndrome in comparison to Alzheimer disease in the general (non-Down syndrome) population. This 2-year randomized, double-blind, placebo-controlled trial assessed […]
Sertraline for the treatment of depression in Alzheimer disease
Rosenberg, Paul B.,
Drye, Lea T.,
Martin, Barbara K.,
Frangakis, Constantine,
Mintzer, Jacobo E.,
Weintraub, Daniel,
Porsteinsson, Anton P.,
Schneider, Lon S.,
Rabins, Peter V.,
Munro, Cynthia A.,
Meinert, Curtis L.,
Lyketsos, Constantine G.
Objective: Depression is common in Alzheimer disease (AD), and antidepressants are commonly used for its treatment, however, evidence for antidepressant efficacy in this population is lacking. The authors conducted a multicenter, randomized, placebo-controlled trial titled “Depression in Alzheimer’s Disease-2” to assess the efficacy and tolerability of sertraline for depression in AD.; Methods: One hundred thirty-one […]
Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size
Román, Gustavo C.,
Salloway, Stephen,
Black, Sandra E.,
Royall, Donald R.,
DeCarli, Charles,
Weiner, Michael W.,
Moline, Margaret,
Kumar, Dinesh,
Schindler, Rachel,
Posner, Holly
Background and Purpose: We sought to assess the efficacy and safety of donepezil in patients with vascular dementia (VaD) fulfilling National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences criteria.; Methods: This international, multicenter, 24-week trial was conducted from March 2003 to August 2005. Patients (N=974; mean age, 73.0 […]